Trajenta® (Linagliptin): New Data On Safety And Efficacy In Type 2 Diabetes Patients With Moderate To Severe Renal Impairment

Date: Jun-26-2013Data presented at the American Diabetes Association (ADA) 73rd Scientific Sessions® provides insights for use of Trajenta® (linagliptin) in adults with Type 2 Diabetes (T2D) with moderate to severe renal impairment

Boehringer Ingelheim and Eli Lilly and Company  have announced results from a new study that demonstrated linagliptin showed statistically significant reduction in blood glucose levels (HbA1C) in adult patients with Type 2 Diabetes (T2D) with moderate to severe renal impairment (RI), compared with those receiving placebo (12 weeks). Most patients had T2D for more than ten years (76%) and were on insulin (86%). After 12 weeks, patients on placebo switched to glimepiride up to 52 weeks. The study found that patients treated with linagliptin had lower rates of hypoglycaemia and less weight gain than those who received glimepiride.1

"These are important findings for physicians managing patients with Type 2 Diabetes and renal impairment, which we are seeing more and more in today's practice," said Professor Markuu Laakso, Professor of Medicine at the Department of Medicine, University of Kuopio, Finland. "Approximately half of patients living with Type 2 Diabetes are also at risk of declining renal function, and treatment options for these patients can be limited. Ensuring that optimum blood glucose levels are achieved paired with the prevention of hypoglycaemic events is becoming more of a challenge."

These new findings were derived from a doubleblind trial including 235 T2D patients with moderate to severe RI (estimated glomerular filtration rate
Greater mean reduction in baseline HbA1c at 12 weeks for patients treated with linagliptin vs. placebo (0.53±0.06% vs. 0.08±0.07%; p
In the 40 week extension, HbA1c was lower with linagliptin vs. glimepiride (difference is not statistically significant)
Less frequent hypoglycaemic events experienced with linagliptin vs. glimepiride (57.9% vs. 69.3%)
Weight neutrality for linagliptin versus weight gain for patients treated with placebo followed by glimepiride (mean increase after 52 wks 0.06 kg linagliptin vs. 1.74 kg placebo/glimepiride)
The US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory authorities worldwide approved linagliptin for the treatment of adult patients with T2D as monotherapy or in combination with metformin, with metformin and a sulphonylurea, and as addon therapy to insulin. With linagliptin, no dose adjustment is required regardless of declining renal function or hepatic impairment.2,3

About Linagliptin

Linagliptin (5 mg, once daily) is marketed in Europe as Trajenta® (linagliptin) and in the U.S. as Tradjenta® (linagliptin), as a oncedaily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D. Linagliptin should not be used in patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).2,3

View drug information on Tradjenta.
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.